Trials / Completed
CompletedNCT00405249
Safety Study of Elvucitabine in HIV-1 Subjects
14-Day Randomized Double-Blind Comparative Viral Kinetic Study of Elvucitabine Versus Lamivudine Once Daily to HIv-1 Subjects With M184V
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Thomas Jefferson University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.
Detailed description
This is a 14 day on treat/14 day off treatment randomized, double blind viral kinetic study of elvucitabine versus lamivudine administered once daily to HIV infected subjects with a documented M184V variant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | elvucitabine |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2006-11-30
- Last updated
- 2009-02-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00405249. Inclusion in this directory is not an endorsement.